- Home
- MOLN vs CHRS Comparison
MOLN vs CHRS Comparison
Compare MOLN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- CHRS
- Stock Information
- Founded
- MOLN 2004
- CHRS 2010
- Country
- MOLN Switzerland
- CHRS United States
- Employees
- MOLN N/A
- CHRS 235
- Industry
- MOLN
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOLN
- CHRS Health Care
- Exchange
- MOLN Nasdaq
- CHRS Nasdaq
- Market Cap
- MOLN 192.4M
- CHRS 134.4M
- IPO Year
- MOLN 2021
- CHRS 2014
- Fundamental
- Price
- MOLN $5.04
- CHRS $1.16
- Analyst Decision
- MOLN
- CHRS Strong Buy
- Analyst Count
- MOLN 0
- CHRS 4
- Target Price
- MOLN N/A
- CHRS $5.38
- AVG Volume (30 Days)
- MOLN 5.7K
- CHRS 2.4M
- Earning Date
- MOLN 03-13-2025
- CHRS 03-12-2025
- Dividend Yield
- MOLN N/A
- CHRS N/A
- EPS Growth
- MOLN N/A
- CHRS N/A
- EPS
- MOLN N/A
- CHRS N/A
- Revenue
- MOLN $7,105,397.00
- CHRS $304,340,000.00
- Revenue This Year
- MOLN N/A
- CHRS $2.47
- Revenue Next Year
- MOLN $29.41
- CHRS N/A
- P/E Ratio
- MOLN N/A
- CHRS N/A
- Revenue Growth
- MOLN N/A
- CHRS 44.19
- 52 Week Low
- MOLN $3.32
- CHRS $0.66
- 52 Week High
- MOLN $12.70
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- MOLN 41.97
- CHRS 38.01
- Support Level
- MOLN $5.22
- CHRS $1.03
- Resistance Level
- MOLN $5.35
- CHRS $1.39
- Average True Range (ATR)
- MOLN 0.12
- CHRS 0.14
- MACD
- MOLN -0.03
- CHRS -0.03
- Stochastic Oscillator
- MOLN 0.00
- CHRS 14.04
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.